Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 2/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | GRM8 | O00222 | 2/20 | 0.82 |
| ▸ | GRM6 | O15303 | 2/20 | 0.82 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.82 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.82 |
| ▸ | GSR | P00390 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.82 |
| ▸ | GRM5 | P41594 | 1/20 | 0.82 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.82 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.82 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.82 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.82 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL9165715 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL9276090 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL19878277 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL9276094 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL352341 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL1634485 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL8429219 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL2443861 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL28971512 | 0.98 | PMP22 (0.83) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL28756768 | 0.94 | ALOX15 (0.76) | PMP22ALOX15BLMKMT2AGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110542731-B | Fingerprint detection method of white ginseng fungus | 湖南宇山玉月农业科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-108949826-A | The recombined glandulae correlation viral vectors and its construction method of carrying MAGE-A3 mutant antigen gene and application | 北京安斯晨睿生物科技有限公司 | 2018-12-07 | — | — | CN | claimed |
| US-20150273088-A1 | ZAPRINAST ANALOGUES AS GLUTAMINASE INHIBITORS AND METHODS TO PREDICT RESPONSE THERETO | WASHINGTON UNIVERSITY (US) | 2015-10-01 | — | — | US | claimed |
| WO-2003002135-A2 | HERBAL COMPOSITION | PRETORIUS ANDRIES PHILIPPUS (ZA) | 2003-01-09 | — | — | WO | claimed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| US-4225614-A | Method of treatment for mucocutaneous herpes simplex infections | AKTIEBOLAGET DRACO (SE) | 1980-09-30 | — | — | US | claimed |
| US-12583896-B2 | Caged-degron-based molecular feedback circuits and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-24 | — | — | US | disclosed |
| US-12016869-B2 | Dairy product and process | FONTERRA CO-OPERATIVE GROUP LIMITED (NZ) | 2024-06-25 | — | — | US | disclosed |
| US-20240201296-A1 | Magnetic Resonance Spectroscopy Frequency and Phase Correction | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240165070-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-23 | — | — | US | disclosed |
| CN-118028131-A | Microecological preparation product for simultaneously improving depression or anxiety and sleep | 浙江妙活氏生物科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2024-04-11 | — | — | US | disclosed |
| CN-116973575-A | Application of biomarker in preparation of kit for detecting Du's muscular dystrophy carrier | 南京市妇幼保健院 | 2023-10-31 | — | — | CN | disclosed |
| WO-1993013794-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5223638-A | Reacting primary or secondary amine with carbon dioxide in presence of strong amidine or guanidine base to form ammonium carbamate salt, reacting in polar aprotic solvent with primary or secondary hydrocarbyl halide | MONSANTO COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0535088-A1 | CHIMERIC TOXINS WITH IMPROVED INTER-DOMAIN GEOMETRY | THE UNIVERSITY HOSPITAL (US) | 1993-04-07 | — | — | EP | disclosed |
| CN-1069735-A | The synthetic fast and screening of peptide mimics | LILLY CO ELI (US) | 1993-03-10 | — | — | CN | disclosed |
| EP-0511948-A2 | Preparation of urethane and carbonate products | MONSANTO COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
| WO-1991019745-A1 | CHIMERIC TOXINS WITH IMPROVED INTER-DOMAIN GEOMETRY | THE UNIVERSITY HOSPITAL (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0035831-B1 | METHOD FOR MAKING GENETICALLY MODIFIED MICROORGANISMS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165070-A1 | GLUTAMINASE INHIBITOR THERAPY | ASNS, GLS, GLS2 | PMP22 3456/4885ALOX15 1241/4885BLM 3384/4885 |
| US-20150273088-A1 | ZAPRINAST ANALOGUES AS GLUTAMINASE INHIBITORS AND METHODS TO PREDICT RESPONSE THERETO | GLS, GLS2, GLUL | PMP22 3150/4885ALOX15 3000/4885BLM 1913/4885 |
| US-12583896-B2 | Caged-degron-based molecular feedback circuits and methods of using the same | RPRD2, STUB1, SSU72 | PMP22 4594/4885ALOX15 4749/4885BLM 586/4885 |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, ACADM | PMP22 255/4885ALOX15 1505/4885BLM 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.